Journal article

Authors list: Burghaus, Stefanie; Drazic, Predrag; Woelfler, Monika; Mechsner, Sylvia; Zeppernick, Magdalena; Meinhold-Heerlein, Ivo; Mueller, Michael D.; Rothmund, Ralf; Vigano, Paola; Becker, Christian M.; Zondervan, Krina T.; Beckmann, Matthias W.; Fasching, Peter A.; Berner-Gatz, Sibylle; Gruenewald, Felix S.; Hund, Martin; Kastner, Peter; Klammer, Martin; Laubender, Ruediger P.; Wegmeyer, Heike; Wienhues-Thelen, Ursula-Henrike; Renner, Stefan P.

Publication year: 2024

Pages: 305-314

Journal: International Journal of Gynecology & Obstetrics

Volume number: 164

Issue number: 1

ISSN: 0020-7292

eISSN: 1879-3479

Open access status: Hybrid

DOI Link: https://doi.org/10.1002/ijgo.15062

Publisher: Wiley

Abstract: 
Objective To evaluate blood-based biomarkers to detect endometriosis and/or adenomyosis across nine European centers (June 2014-April 2018).Methods This prospective, non-interventional study assessed the diagnostic accuracy of 54 blood-based biomarker immunoassays in samples from 919 women (aged 18-45 years) with suspicion of endometriosis and/or adenomyosis versus symptomatic controls. Endometriosis was stratified by revised American Society for Reproductive Medicine stage. Symptomatic controls were "pathologic symptomatic controls" or "pathology-free symptomatic controls". The main outcome measure was receiver operating characteristic-area under the curve (ROC-AUC) and Wilcoxon P values corrected for multiple testing (q values).Results CA-125 performed best in "all endometriosis cases" versus "all symptomatic controls" (AUC 0.645, 95% confidence interval [CI] 0.600-0.690, q < 0.001) and increased (P < 0.001) with disease stage. In "all endometriosis cases" versus "pathology-free symptomatic controls", S100-A12 performed best (AUC 0.692, 95% CI 0.614-0.769, q = 0.001) followed by CA-125 (AUC 0.649, 95% CI 0.569-0.729, q = 0.021). In "adenomyosis only cases" versus "symptomatic controls" or "pathology-free symptomatic controls", respectively, the top-performing biomarkers were sFRP-4 (AUC 0.615, 95% CI 0.551-0.678, q = 0.045) and S100-A12 (AUC 0.701, 95% CI 0.611-0.792, q = 0.004).Conclusion This study concluded that no biomarkers tested could diagnose or rule out endometriosis/adenomyosis with high certainty.

Harvard Citation style: Burghaus, S., Drazic, P., Woelfler, M., Mechsner, S., Zeppernick, M., Meinhold-Heerlein, I., et al. (2024) Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study, International Journal of Gynecology & Obstetrics, 164(1), pp. 305-314. https://doi.org/10.1002/ijgo.15062

APA Citation style: Burghaus, S., Drazic, P., Woelfler, M., Mechsner, S., Zeppernick, M., Meinhold-Heerlein, I., Mueller, M., Rothmund, R., Vigano, P., Becker, C., Zondervan, K., Beckmann, M., Fasching, P., Berner-Gatz, S., Gruenewald, F., Hund, M., Kastner, P., Klammer, M., Laubender, R., ...Renner, S. (2024). Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. International Journal of Gynecology & Obstetrics. 164(1), 305-314. https://doi.org/10.1002/ijgo.15062